Trial Summary
What is the purpose of this trial?
The proposed research consists of engagements with terminal cancer patients and their friends and family as they engage in end-of-life planning.
Do I need to stop taking my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Post-Mortem Plan, Project Debrief, Retrospective, Project Recap, Wrap-Up Meeting, Lessons Learned Meeting for end-of-life planning for cancer?
The research highlights the importance of improving end-of-life care by focusing on quality and symptom management, which are key components of effective end-of-life planning. This suggests that structured planning and review processes, like those in the treatment, can enhance the quality of care for patients at the end of life.12345
Is the end-of-life planning treatment generally safe for humans?
Is the treatment in the trial 'End-of-Life Planning for Cancer' a promising treatment?
Research Team
JB
Jed Brubaker
Principal Investigator
University of Colorado, Boulder
Eligibility Criteria
This trial is for adults with metastatic cancer who have online accounts and data, as well as their adult family or friends willing to participate in end-of-life planning activities. There are no specific exclusion criteria listed.Inclusion Criteria
Life-limited adults diagnosed with metastatic cancer who have online accounts and data
Adult family/loved ones of the diagnosed adult who are willing to participate in planning activities
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Engagement and Planning
Participants engage in interviews to identify end-of-life needs and wishes, and develop post-mortem plans.
Varies based on participant needs
Multiple visits (in-person or virtual)
Implementation and Support
Participants and their networks perform tasks to implement the post-mortem plan, with support from the study team.
Ongoing
Regular check-ins based on participant preferences
Follow-up
Participants are monitored for changes in social and technical circumstances, with ongoing support provided.
5 years
Treatment Details
Interventions
- Post-Mortem Plan (Other)
Trial OverviewThe study focuses on the process of end-of-life planning concerning online accounts and data management for terminal cancer patients, involving their close ones in these preparations.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Post-Mortem PlanExperimental Treatment1 Intervention
Following the death of the terminally ill participant, investigators will work with networks as the wishes of the deceased are executed. Continued engagement at this point will allow us to provide support to the network during a difficult period or time while also identifying shortcomings in our plans and systemic challenges to postmortem planning. Working with those who are grieving is a delicate proposition, but one with which my students and I have extensive experience.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
University of Colorado HealthAurora, CO
Loading ...
Who Is Running the Clinical Trial?
University of Colorado, Denver
Lead Sponsor
Trials
1842
Patients Recruited
3,028,000+
U.S. National Science Foundation
Collaborator
Trials
35
Patients Recruited
9,000+
Findings from Research
NCBI (Pubmed)
pubmed.ncbi.nlm.nih.gov
Effects of a patient/family-centered practice change on the quality and cost of intensive care: research protocol.Radwin, LE., Ananian, L., Cabral, HJ., et al.[2015]
NCBI (Pubmed)
pubmed.ncbi.nlm.nih.gov
Palliative care at the end of life: comparing quality in diverse settings.Paice, JA., Muir, JC., Shott, S.[2019]
NCBI (Pubmed)
pubmed.ncbi.nlm.nih.gov
Use of the quality improvement process in assessing end-of-life care in the nursing home.Vandenberg, EV., Tvrdik, A., Keller, BK.[2006]
A quality improvement project at the Thomas Fitzgerald State Veterans Home led to significant enhancements in end-of-life care, including a 22% reduction in pain, 25% in dyspnea, and 30% in other uncomfortable symptoms, as reported by representatives of the deceased.
The project highlighted the importance of interdisciplinary teamwork and patient representative surveys in identifying areas for improvement, resulting in better overall quality of care and spiritual support, although challenges remained in managing emotional issues like depression and anxiety.
NCBI (Pubmed)
pubmed.ncbi.nlm.nih.gov
Use of the quality improvement process in assessing end-of-life care in the nursing home.Vandenberg, EV., Tvrdik, A., Keller, BK.[2015]
NCBI (Pubmed)
pubmed.ncbi.nlm.nih.gov
Auditing palliative care in one general practice over eight years.Holden, JD.[2019]
NCBI (Pubmed)
pubmed.ncbi.nlm.nih.gov
Aiming for zero preventable deaths: using death review to improve care and reduce harm.Zimmerman, R., Pierson, S., McLean, R., et al.[2019]
NCBI (Pubmed)
pubmed.ncbi.nlm.nih.gov
Evaluating and implementing data and safety monitoring plans.Terrin, ML.[2016]
NCBI (Pubmed)
pubmed.ncbi.nlm.nih.gov
A primer of drug safety surveillance: an industry perspective. Part I: Information flow, new drug development, and federal regulations.Allan, MC.[2019]
NCBI (Pubmed)
pubmed.ncbi.nlm.nih.gov
[Consensus conference on providing information of adverse events to patients and relatives].Martín-Delgado, MC., Fernández-Maillo, M., Bañeres-Amella, J., et al.[2015]
NCBI (Pubmed)
pubmed.ncbi.nlm.nih.gov
Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study.Maund, E., Tendal, B., Hróbjartsson, A., et al.[2023]
NCBI (Pubmed)
pubmed.ncbi.nlm.nih.gov
Social and healthcare professionals' experiences of end-of-life care planning and documentation in palliative care.Kuusisto, A., Saranto, K., Korhonen, P., et al.[2023]
NCBI (Pubmed)
pubmed.ncbi.nlm.nih.gov
Symptoms, treatment and "dying peacefully" in terminally ill cancer patients: a prospective study.Georges, JJ., Onwuteaka-Philipsen, BD., van der Heide, A., et al.[2018]
NCBI (Pubmed)
pubmed.ncbi.nlm.nih.gov
End-of-life transitions for family member on the solid tumour oncology ward: the 3 Wishes Project.Day, G., Bear, D., Swinton, M., et al.[2021]
A systematic review of 45 Comprehensive Cancer Control (CCC) Plans revealed that 91% included the keyword 'end-of-life,' indicating a strong recognition of EOL issues in cancer care.
The most common EOL goals focused on care usage, access to care, and raising awareness, with strategies emphasizing research and education for both providers and the public, which can enhance future CCC planning efforts.
NCBI (Pubmed)
pubmed.ncbi.nlm.nih.gov
End-of-life content in Comprehensive Cancer Control Plans: a systematic review.Theis, KA., Rao, JK., Anderson, LA., et al.[2023]
In a study of 200 patients with advanced non-small cell lung cancer, specific elements of end-of-life discussions (like prognosis and hospice preferences) did not significantly impact patients' quality of life or the actual care they received at the end of life.
However, the compassion shown by oncologists was linked to improvements in patients' quality of life and depressive symptoms, suggesting that the emotional support from healthcare providers plays a crucial role in end-of-life care.
NCBI (Pubmed)
pubmed.ncbi.nlm.nih.gov
Elements of End-of-Life Discussions Associated With Patients' Reported Outcomes and Actual End-of-Life Care in Patients With Pretreated Lung Cancer.Hasegawa, T., Okuyama, T., Uemura, T., et al.[2023]
References
Effects of a patient/family-centered practice change on the quality and cost of intensive care: research protocol. [2015]
Palliative care at the end of life: comparing quality in diverse settings. [2019]
Use of the quality improvement process in assessing end-of-life care in the nursing home. [2006]
Use of the quality improvement process in assessing end-of-life care in the nursing home. [2015]
Auditing palliative care in one general practice over eight years. [2019]
Aiming for zero preventable deaths: using death review to improve care and reduce harm. [2019]
Evaluating and implementing data and safety monitoring plans. [2016]
A primer of drug safety surveillance: an industry perspective. Part I: Information flow, new drug development, and federal regulations. [2019]
[Consensus conference on providing information of adverse events to patients and relatives]. [2015]
Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study. [2023]
Social and healthcare professionals' experiences of end-of-life care planning and documentation in palliative care. [2023]
Symptoms, treatment and "dying peacefully" in terminally ill cancer patients: a prospective study. [2018]
End-of-life transitions for family member on the solid tumour oncology ward: the 3 Wishes Project. [2021]
End-of-life content in Comprehensive Cancer Control Plans: a systematic review. [2023]
Elements of End-of-Life Discussions Associated With Patients' Reported Outcomes and Actual End-of-Life Care in Patients With Pretreated Lung Cancer. [2023]